Takeda Pharmaceutical, a Japan-based drugs company, has agreed to buy one of its corporate venturing unit’s portfolio companies, Envoy Therapeutics, for up to $140m. Takeda Ventures invested in Envoy’s $8m series A round in October 2009 and partnered with the developer of drugs for neurological and psychiatric diseases. The other investors in the A round…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
